StockNews.com Lowers USANA Health Sciences (NYSE:USNA) to Buy

USANA Health Sciences (NYSE:USNA – Get Rating) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Separately, DA Davidson increased their price objective on shares of USANA Health Sciences from $52.50 to $56.00 in a research report on Wednesday, April 26th.

USANA Health Sciences Stock Up 1.4 %

Shares of USANA Health Sciences stock traded up $0.87 during mid-day trading on Friday, hitting $62.77. The stock had a trading volume of 42,458 shares, compared to its average volume of 70,563. The firm has a market cap of $1.21 billion, a P/E ratio of 18.52 and a beta of 0.78. The firm has a 50-day moving average of $64.12 and a two-hundred day moving average of $59.22. USANA Health Sciences has a 12-month low of $48.61 and a 12-month high of $76.58.

Insiders Place Their Bets

In other news, Director John Turman Fleming sold 1,250 shares of the firm’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $67.04, for a total value of $83,800.00. Following the sale, the director now directly owns 2,153 shares in the company, valued at approximately $144,337.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, President Jim Brown sold 12,202 shares of the firm’s stock in a transaction on Monday, May 8th. The shares were sold at an average price of $66.48, for a total value of $811,188.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Turman Fleming sold 1,250 shares of the firm’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $67.04, for a total transaction of $83,800.00. Following the completion of the sale, the director now owns 2,153 shares in the company, valued at $144,337.12. The disclosure for this sale can be found here. Insiders have sold a total of 24,581 shares of company stock worth $1,605,195 in the last ninety days. 0.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Royce & Associates LP raised its stake in USANA Health Sciences by 12.2% during the 1st quarter. Royce & Associates LP now owns 23,507 shares of the company’s stock worth $1,479,000 after acquiring an additional 2,547 shares in the last quarter. Ameriprise Financial Inc. raised its stake in USANA Health Sciences by 5.1% during the 1st quarter. Ameriprise Financial Inc. now owns 70,825 shares of the company’s stock worth $4,455,000 after acquiring an additional 3,405 shares in the last quarter. JPMorgan Chase & Co. raised its stake in USANA Health Sciences by 7.7% during the 1st quarter. JPMorgan Chase & Co. now owns 81,627 shares of the company’s stock worth $5,135,000 after acquiring an additional 5,848 shares in the last quarter. Providence Capital Advisors LLC grew its position in USANA Health Sciences by 6,189.9% during the 1st quarter. Providence Capital Advisors LLC now owns 6,856 shares of the company’s stock worth $109,000 after purchasing an additional 6,747 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in USANA Health Sciences during the 1st quarter worth $241,000. 52.62% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

(Get Rating)

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm’s brands include Procosa and MagneCal D. The company was founded by Myron W.